During a routine outpatient visit, a 32-year-old female reports a four-week history of unq… — USMLE Step 3

During a routine outpatient visit, a 32-year-old female reports a four-week history of unquenchable thirst and frequent urination. She states she has been drinking up to 6 liters of water daily and wakes up three to four times per night to void.

Her past psychiatric history is significant for severe, treatment-resistant bipolar I disorder. In her twenties, she experienced recurrent manic episodes with psychotic features that failed to respond to valproate and olanzapine. She was subsequently stabilized on lithium therapy three years ago. A recent psychiatric evaluation confirmed her mood is completely stable, and her psychiatrist strongly recommended avoiding any changes to her psychotropic regimen.

Vital signs are within normal limits. Physical examination reveals dry oral mucosa.

Laboratory data is as follows:

Laboratory Test	Result	Reference Range
Serum sodium	$146 \text{ mEq/L}$	$136-145 \text{ mEq/L}$
Serum potassium	$4.1 \text{ mEq/L}$	$3.5-5.0 \text{ mEq/L}$
Serum creatinine	$1.1 \text{ mg/dL}$	$0.6-1.2 \text{ mg/dL}$
Serum lithium	$0.9 \text{ mEq/L}$	$0.6-1.2 \text{ mEq/L}$
Urine specific gravity	$1.003$	$1.005-1.030$
Urine osmolality	$145 \text{ mOsm/kg}$	$500-850 \text{ mOsm/kg}$

Which of the following is the most appropriate next step in the management of this patient?

Initiate oral amiloride therapyCevap
B
Advise strict restriction of daily free water intake
C
Administer intranasal desmopressin
D
Discontinue lithium and initiate carbamazepine
E
Order a supervised water deprivation test

Cevap

The correct answer is to initiate oral amiloride therapy to manage the lithium-induced nephrogenic diabetes insipidus while maintaining her necessary psychiatric medication.

The correct approach is to prescribe amiloride. The patient has developed lithium-induced nephrogenic diabetes insipidus (NDI). Lithium enters the principal cells of the renal collecting duct through epithelial sodium channels (ENaC) and interferes with the normal intracellular response to antidiuretic hormone (ADH). Because this patient has a history of severe, treatment-resistant bipolar disorder that is currently stable, discontinuing lithium carries an unacceptably high risk of relapse. Amiloride is the treatment of choice in this situation; it is a potassium-sparing diuretic that blocks the ENaC channels, thereby preventing further lithium accumulation in the principal cells and partially restoring the kidneys' ability to concentrate urine.

Adım Adım Çözüm

Interpret the clinical presentation and laboratory data.

The patient has polyuria, polydipsia, high-normal serum sodium (

146 \text{ mEq/L}

), and dilute urine (osmolality

145 \text{ mOsm/kg}

) in the setting of chronic lithium use, confirming lithium-induced nephrogenic diabetes insipidus (NDI).

Establishing the correct diagnosis is the prerequisite for appropriate therapeutic modification.

Evaluate the viability of discontinuing the offending agent.

The patient has severe, treatment-resistant bipolar disorder that is only stable on lithium, and psychiatric consultation strongly advises against cessation.

Discontinuing lithium is generally the first-line treatment for lithium-induced NDI, but the risk of severe psychiatric relapse outweighs the renal benefits in this specific patient.

Determine the optimal pharmacologic adjunct to treat the side effect.

Amiloride is selected because it blocks ENaC channels in the collecting duct, preventing lithium entry into the principal cells.

This targeted intervention mitigates the toxicity and allows the patient to safely continue her essential psychiatric therapy.

Anahtar Kavram

Management of lithium-induced nephrogenic diabetes insipidus in patients requiring continued lithium therapy involves the addition of amiloride, which blocks lithium entry into the principal cells of the collecting duct.

Tahmini Süre:1m 30s

Soru

Cevap

Adım Adım Çözüm

Anahtar Kavram

Sık Yapılan Hatalar

Konular

Bu konudan daha fazla soru